Recent Updates
Recently added Catalysts
JAZZ Positive Sentiment Score: 70/100

Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24th Annual Needham Healthcare Conference. Company...

Key Takeaway: Jazz Pharmaceuticals plc will participate in the 24th Annual Needham Healthcare Conference on April 9, 2025. The event will feature a fireside chat with company management, aimed at discussing the company's advancements and strategies. An audio webcast of the event will be available on their investor relations website and will be archived for 30 days. This participation highlights Jazz's commitment to innovation and development in the biopharma sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent healthcare conference indicates visibility.
  • Management engagement in a fireside chat may attract investor interest.
  • The company showcases a diverse portfolio of life-changing therapies.

Full Press Release Details

DUBLIN , March 26, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the Company will participate in the 24 th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 9, 2025 , at 9:45 a.m. PT / 12:45 p.m. ET / 5:45 p.m. IST .
An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations . A replay of the webcasts will be archived on the website for 30 days.
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Investors: Jeff Macdonald Executive Director, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland +353 1 634 3211 U.S. +1 650 496 2717
Media: Kristin Bhavnani Head of Global Corporate Communications Jazz Pharmaceuticals plc [email protected] Ireland +353 1 637 2141 U.S. +1 215 867 4948
SOURCE Jazz Pharmaceuticals plc

21 %

Frequently Asked Questions

When will Jazz Pharmaceuticals participate in the Needham Conference?

Jazz Pharmaceuticals will participate on April 9, 2025, at 9:45 a.m. PT.

Where can I find the audio webcast of the event?

The audio webcast will be available on Jazz Pharmaceuticals' investor section.

How long will the webcast replay be available?

The webcast replay will be archived for 30 days.

What type of medicines does Jazz Pharmaceuticals develop?

Jazz Pharmaceuticals develops life-changing treatments for serious diseases.

What is Jazz Pharmaceuticals' focus area?

Their focus areas include oncology, neuroscience, and therapies for sleep disorders.

Last updated: Mar 26, 2025